Former FDA commissioner Crawford faces fines and probation in stock case

Share this article:
Former FDA commissioner Lester Crawford faces a $50,000 fine and probation but no jail time for lying about ownership of illegally held stocks, the Associated Press reports. Crawford and federal prosecutors have both agreed to the fine and some form of probation. His ultimate sentence will be determined by Magistrate Judge Deborah Robinson, according to documents filed with the US district Court in Washington, DC. Sentencing is scheduled for Jan. 23. Crawford pleaded guilty in October to charges of having a conflict of interest and false reporting of information about stocks he and his wife owned in food, beverage and medical device companies he regulated while head of the FDA. The US Attorney’s office recommended the $50,000 fine, saying it would exceed the roughly $39,000 Crawford and his wife Cathy, made from exercising options and in dividends from the forbidden stocks they held in the FDA-regulated companies. The government also recommended Crawford be sentenced to probation and community service but skip jail time. Crawford could face up to six months in jail under sentencing guidelines. Crawford abruptly resigned from the FDA in September 2005 but gave no reason for leaving. He held the job of commissioner for only two months following confirmation by the Senate.
Share this article:

Email Newsletters

More in News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...